Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zhenyuan Capsule for coronary heart disease with anxiety or depression
ChiCTR2100041994Phase 4Recruiting
- Sponsor
- China-Japan Union Hospital of Jilin University
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Zhenyuan Capsule in coronary arteriosclerosis, anxiety disorder and major depressive disorder (MDD) (4 arms), sponsored by China-Japan Union Hospital of Jilin University. Primary endpoints: HAMA score at 6 weeks, HAMD score at 6 weeks and 12 more. Started Jan 2021; status: recruiting.
02
Drugs
Zhenyuan Capsule
03
Conditions
coronary arteriosclerosisanxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2100041994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041994.